4.0 Article

Bone tumours-What's new in the 2020 WHO classification and beyond

Related references

Note: Only part of the references are listed.
Article Cell Biology

H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases

Benedikt Leinauer et al.

Summary: Giant cell tumour of bone (GCTB) is characterized by a specific mutation of the histone gene H3F3A in up to 92% of cases, and our study analyzed three H3F3A-mutated bone tumours without detectable giant cells. The absence of giant cells in these lesions presents a challenge for diagnosis solely based on histology, but detection of the H3.3 p.G34W mutation can aid in diagnosing these lesions as GCTB.

HISTOPATHOLOGY (2021)

Article Pathology

FOS Expression in Osteoid Osteoma and Osteoblastoma A Valuable Ancillary Diagnostic Tool

Fernanda Amary et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)

Article Oncology

Activating mutations in the MAP-kinase pathway define non-ossifying fibroma of bone

Daniel Baumhoer et al.

JOURNAL OF PATHOLOGY (2019)

Article Multidisciplinary Sciences

Recurrent rearrangements of FOS and FOSB define osteoblastoma

Matthew W. Fittall et al.

NATURE COMMUNICATIONS (2018)

Article Orthopedics

Does osteofibrous dysplasia progress to adamantinoma and how should they be treated?

D. W. Scholfield et al.

BONE & JOINT JOURNAL (2017)

Letter Clinical Neurology

Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis

Martin Hasselblatt et al.

ACTA NEUROPATHOLOGICA (2016)